The Europe Controlled Release Drug Delivery Market would witness market growth of 10.2% CAGR during the forecast period (2023-2030).
The past few years have seen increased pharmaceutical investment in many nations owing to the rising demand for medicines and treatments. The consistently expanding R&D spending of pharmaceutical companies is directed at forming effective treatments for noncommunicable chronic problems, including cancer and diabetes.
Drug delivery devices are being used more frequently as a result of the rising cancer burden. Because patients could not tolerate high doses and the side effects associated with high doses, the predominance of chronic illnesses led to an increase in the demand for controlled release drug delivery.
It is anticipated that, by 2025, the total number of cancer cases in the EU countries will increase from the 2.75 million instances reported in 2015 to more than 3.1 million cases annually due to demographic factors. In addition, more people than ever before are coping with cancer. In Europe, 16–17 million persons are believed to be either undergoing cancer treatment or have achieved long-term remission after treatment. This number is anticipated to increase dramatically during the following several years. 85% of deaths in the EU are caused by chronic diseases such as cardiovascular disease, cancer, diabetes, chronic respiratory disorders, and mental illness. These conditions make up the list of specific causes of mortality. All forms of cancer rank first among the leading causes of death in people under 65, while cardiovascular disease is first among those over 65.
Germany is a prominent market for controlled release drug delivery in Europe, and its growth is largely related to growing R&D spending for developing cutting-edge drug delivery systems. The Nose-to-Brain-patch (N2B-patch), a project sponsored by the EU itself, aims to develop a revolutionary technology for the treatment of multiple sclerosis (MS) by developing a "nose to the brain" medication delivery system. This region's two most commercially successful products are transdermal patches and transdermal semisolids. Due to changes brought about by a decline in health care, the region is experiencing an increase in mortality from cardiovascular diseases. The market in this region will grow faster due to all these elements.
The Germany market dominated the Europe Controlled Release Drug Delivery Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7,194.3 million by 2030. The UK market is registering a CAGR of 9.3% during (2023 - 2030). Additionally, The France market would display a CAGR of 11% during (2023 - 2030).
Based on Release Mechanism, the market is segmented into Feedback Regulated Drug Delivery Systems, Activation-modulated Drug Delivery Systems, Chemically Activated, Polymer Based Systems and Micro Reservoir Partition Controlled Drug Delivery Systems. Based on Technology, the market is segmented into Targeted Delivery, Coacervation, Micro Encapsulation, Transdermal, Implants, Wurster Technique and Others. Based on Application, the market is segmented into Oral Controlled-drug delivery Systems, Metered Dose Inhalers, Injectable, Transdermal & Ocular Patches and Infusion Pumps & Drug Eluting Stents. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Controlled Release Drug Delivery Market is Projected to reach USD 106.3 Billion by 2030, at a CAGR of 10.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Merck & Co., Inc., Alkermes PLC, Pfizer, Inc., Assertio Holdings, Inc. (Assertio Therapeutics, Inc.), Lonza Group AG (Capsugel), Colorcon, Inc. (BPSI Holdings LLC.), Corium, LLC (Gurnet Point Capital), Adare Pharma Solutions, and Coating Place, Inc.
By Release Mechanism
By Technology
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 